Pubblicazioni

Autori:

Antonucci, Emilia; Migliaccio, Ludovica; Abbattista, Maria; Caronna, Antonella; DE MARCHI, Sergio; Di Giorgio, Angela; Di Giulio, Rosella; Lerede, Teresa; Grazia Garzia, Maria; Martinelli, Ida; Mastroiacovo, Daniela; Marzolo, Marco; Montevecchi, Elisa; Pastori, Daniele; Pignatelli, Pasquale; Poli, Daniela; Ria, Luigi; Santoliquido, Angelo; Testa, Sophie; Palareti, Gualtiero; POST VTE Investigators, Start

Titolo:

Treatment Decision-Making of Secondary Prevention After Venous Thromboembolism: Data From the Real-Life START2-POST-VTE Register

Anno:

2020

Tipologia prodotto:

Articolo in Rivista

Tipologia ANVUR:

Articolo su rivista

Lingua:

Inglese

Formato:

Elettronico

Referee:

Sì

Nome rivista:

CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS

ISSN Rivista:

1076-0296

N° Volume:

26

Numero o Fascicolo:

jan-dec 2020

Intervallo pagine:

1-12

Parole chiave:

venous thromboembolism; anticoagulant treatments; duration of anticoagulation

Breve descrizione dei contenuti:

Patients with venous thromboembolism (VTE) should receive a decision on the duration of anticoagulant treatment (AT) that is often not easy to make. Sixteen Italian clinical centers included patients with recent VTE in the START2-POST-VTE register and reported the decisions taken on duration of AT in each patient and the reasons for them. At the moment of this report, 472 (66.9%) of the 705 patients included in the registry were told to stop AT in 59.3% and to extend it in 40.7% of patients. Anticoagulant treatment lasted ≥3 months in >90% of patients and was extended in patients with proximal deep vein thrombosis because considered at high risk of recurrence or had thrombophilic abnormalities. d-dimer testing, assessment of residual thrombus, and patient preference were also indicated among the criteria influencing the decision. In conclusion, Italian doctors stuck to the minimum 3 months AT after VTE, while the secondary or unprovoked nature of the event was not seen as the prevalent factor influencing AT duration which instead was the result of a complex and multifactorial evaluation of each patient.

Note:

registrato ClinicalTrials.gov Identifier: NCT02219984

Pagina Web:

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7573715/

Id prodotto:

119775

Handle IRIS:

11562/1037883

ultima modifica:

30 ottobre 2024

Citazione bibliografica:

Antonucci, Emilia; Migliaccio, Ludovica; Abbattista, Maria; Caronna, Antonella; DE MARCHI, Sergio; Di Giorgio, Angela; Di Giulio, Rosella; Lerede, Teresa; Grazia Garzia, Maria; Martinelli, Ida; Mastroiacovo, Daniela; Marzolo, Marco; Montevecchi, Elisa; Pastori, Daniele; Pignatelli, Pasquale; Poli, Daniela; Ria, Luigi; Santoliquido, Angelo; Testa, Sophie; Palareti, Gualtiero; POST VTE Investigators, Start, Treatment Decision-Making of Secondary Prevention After Venous Thromboembolism: Data From the Real-Life START2-POST-VTE Register «CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS» , vol. 26 , n. jan-dec 2020 , 2020 , pp. 1-12

Consulta la scheda completa presente nel repository istituzionale della Ricerca di Ateneo